Serina Therapeutics (SER) said Wednesday it sold its UniverXome subsidiary.
The deal, which was finalized on Dec. 23, cut $11.2 million in associated subsidiary-level debt, Serina said, adding it now has a debt-free balance sheet.
The unit was set up before Serina's reverse merger with AgeX Therapeutics in March 2024 to hold the legacy assets of the predecessor company, Serina said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。